MYOTONIC DYSTROPHY TYPE 1 (DM1)
Clinical trials for MYOTONIC DYSTROPHY TYPE 1 (DM1) explained in plain language.
Never miss a new study
Get alerted when new MYOTONIC DYSTROPHY TYPE 1 (DM1) trials appear
Sign up with your email to follow new studies for MYOTONIC DYSTROPHY TYPE 1 (DM1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug DYNE-101 aims to ease muscle symptoms in DM1
Disease control Recruiting nowThis Phase 3 trial tests whether DYNE-101 can improve muscle function and daily life in 150 adults with myotonic dystrophy type 1 (DM1). Participants receive either the drug or a placebo by IV every few weeks for 48 weeks. The study measures how quickly people can stand from a ch…
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Phase: PHASE3 • Sponsor: Dyne Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New hope for muscle disease: experimental drug VX-670 enters human trials
Disease control Recruiting nowThis early-stage trial tests the safety and tolerability of a new drug called VX-670 in 52 adults with myotonic dystrophy type 1 (DM1), a genetic condition that causes muscle weakness and other problems. Participants receive either VX-670 or a placebo, and researchers will monito…
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Phase: PHASE1, PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug DYNE-101 aims to ease muscle stiffness in rare disease
Disease control Recruiting nowThis study tests a new medicine, DYNE-101, in 116 adults with myotonic dystrophy type 1 (DM1), a condition that causes muscle weakness and stiffness. The main goals are to check if the drug is safe and if it can reduce muscle stiffness and improve muscle function. Participants re…
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Phase: PHASE1, PHASE2 • Sponsor: Dyne Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Personalized exercise program aims to boost mobility in rare muscle diseases
Symptom relief Recruiting nowThis study tests whether a personalized exercise program can improve balance and physical function in adults with rare neuromuscular disorders like Charcot-Marie-Tooth disease, facioscapulohumeral muscular dystrophy, and myotonic dystrophy type 1. Participants will receive a 12-d…
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Phase: NA • Sponsor: Oslo University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Music therapy tested for rare muscle disease in kids
Symptom relief Recruiting nowThis study explores whether weekly music and movement sessions are practical and enjoyable for children aged 6 to 18 with myotonic dystrophy type 1 (DM1). Over 10 weeks, participants attend 45-minute music classes, undergo physical and cognitive tests, and provide biological samp…
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Phase: NA • Sponsor: Hanns Lochmuller • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
No travel needed: largest Home-Based study of myotonic dystrophy launches
Knowledge-focused Recruiting nowThis study aims to understand why myotonic dystrophy type 1 affects people so differently. Researchers will remotely assess muscle strength, memory, and activity in 1,000 participants, and analyze their DNA from a blood sample. All activities are done from home using a mailed too…
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC